Entecavir Therapy for Patients with Hepatitis B Virus-related Decompensated Cirrhosis | Zendy

In Sung Kim | Zendy; Jun Il Mun | Zendy; Jee Hoon Koo | Zendy; Chang Jun Kang | Zendy; Jean Kyung Bak | Zendy; Jae Yoeun Cheong | Zendy; Sung Won Cho | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Entecavir Therapy for Patients with Hepatitis B Virus-related Decompensated Cirrhosis

Author(s) -

In Sung Kim,

Jun Il Mun,

Jee Hoon Koo,

Chang Jun Kang,

Jean Kyung Bak,

Jae Yoeun Cheong,

Sung Won Cho

Publication year - 2012

Publication title -

korean journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.203

H-Index - 25

eISSN - 2233-6869

pISSN - 1598-9992

DOI - 10.4166/kjg.2012.59.3.224

Subject(s) - medicine , entecavir , cirrhosis , gastroenterology , liver function , hbeag , hepatitis b virus , liver disease , prothrombin time , hepatitis b , hbsag , virus , immunology , lamivudine

Entecavie (ETV) has a potent antiviral effect and low rates of resistance in hepatitis B virus (HBV) and is the first-line monotherapy in patients with HBV-related decompensated cirrhosis. We evaluated the efficacy of 12 months treatment with ETV and tried to determine predictive factors of response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research